Cytosorbents Reports Widened Q1 Loss, Going Concern Warning, and Material Internal Control Weaknesses
CTSO is trading near its 52-week low of $0.499 (14% above the low).
Summary
Cytosorbents reported a significantly widened Q1 net loss, issued a going concern warning, and disclosed persistent material weaknesses in internal controls, despite some improvements in cash burn and operating expenses.
Key Events · Legal and Risk Events · CTSO
-
Going Concern Warning Issued
The company's cash and expected future cash used in operations raise substantial doubt about its ability to continue as a going concern within the next twelve months.
-
Net Loss Widens Significantly
Q1 2026 net loss widened to $5.1 million, compared to a $1.5 million net loss in Q1 2025.
-
Low Cash Position
Unrestricted cash and cash equivalents stood at $4.8 million as of March 31, 2026, with total cash (including restricted) at $6.3 million.
-
Material Weaknesses in Internal Controls
The company disclosed continuing material weaknesses in accounting for stock-based compensation and newly identified weaknesses in financial statement consolidation and reporting.
Analysis · CTSO · Industrial Applications And Services
Cytosorbents Corp's Q1 2026 report highlights severe financial distress, including a going concern warning and a significantly widened net loss of $5.1 million, up from $1.5 million in Q1 2025. The company's unrestricted cash stands at a low $4.8 million, raising substantial doubt about its ability to fund operations for the next twelve months. Further compounding these issues are ongoing material weaknesses in internal controls over financial reporting, continuing from 2024 and newly identified in 2025. Delays in FDA approval for DrugSorb-ATR also impact access to a crucial $2.5 million debt tranche, pushing potential funding beyond 2026. While the company has reduced operating expenses and improved its cash burn from operations, these efforts are overshadowed by the precarious financial position and governance concerns. This filing follows a concurrent 8-K that summarized these results.
At the time of this filing, CTSO was trading at $0.57 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $35.8M. The 52-week trading range was $0.50 to $1.39. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.